RESEARCH PAPER
Influence of oxcarbazepine and its combination with SIB-1893 on body temperature in rats
1
Department of Pathophysiology, Medical University, Lublin, Poland; Department of Physiopathology, Institute of Agricultural Medicine, Lublin, Poland
2
Department of Pathophysiology, Medical University, Lublin, Poland
Corresponding author
Jarogniew J. Łuszczki
Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, 20-090 Lublin, Poland.
Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, 20-090 Lublin, Poland.
J Pre Clin Clin Res. 2008;2(1):31-34
KEYWORDS
ABSTRACT
The aim of the study was to determine the effects of oxcarbazepine (OXC – a newer antiepileptic drug) administered alone and in combination with SIB-1893 (a selective non-competitive metabotropic glutamate subtype 5 [mGlu5] receptor antagonist) on body temperature in freely moving rats. Temperature was monitored using programmed microchips, implanted subcutaneously in Wistar rats, at several time intervals: 0, 5, 10, 20, 30, 45, 60, 90, 120 and 180 min. after intraperitoneal administration of OXC, SIB-1893, and their combination. Statistical evaluation of data with two-way ANOVA with repeated measure on time revealed that SIB-1893 at a dose of 30 mg/kg significantly decreased the body temperature in rats at times ranging from 90-180 min. after drug administration. In contrast, OXC at a dose of 5 mg/kg, administered alone and in combination with SIB-1893 (30 mg/kg), did not significantly alter the body temperature in freely moving rats. Based on this pre-clinical study, one can conclude that OXC administered alone and in combination with SIB-1893 have no effect on body temperature in rats up to 180 min. after intraperitoneal administration of the drugs.
REFERENCES (16)
1.
Dingledine R, Borges K, Bowie D, Traynelis SF: The glutamate receptor ion channels. Pharmacol Rev 1999, 51, 7-61.
2.
Schoepp DD, Schoepp DD, Jane DE, Monn JA: Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38, 1431-1476.
3.
Hara S, Mukai T, Kuriiwa F, Iwata N, Kano S, Endo T: Local changes in oxygen tension and blood fl ow in the brain under hyperthermia induced by intracerebroventricular NMDA in rats. Brain Res 1996, 737, 339-342.
4.
Hara S, Mukai T, Kuriiwa F, Iwata N, Yanase T, Kano S, Endo T: Distinct eff ects of MK-801 and (})-2-amino-5-phosphonopentanoic acid on N-methyl-D-aspartate-induced rise of brain temperature in rats. Life Sci 1997, 61, 289-294.
5.
Turski W, Turski L, Czuczwar SJ, Kleinrok Z: (RS)-alpha-Amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid: wet dog shakes, catalepsy and body temperature changes in rats. Pharmacol Biochem Behav 1981, 15, 545-549.
6.
Gyertyan I, Gigler G, Simo A: The neuroprotective and hypothermic eff ect of GYKI-52466, a non-competitive alpha-amino-3-hydroxy 5-methyl-4-isoxazolepropionic acid-antagonist on histological and behavioural variables in the gerbil global ischemia model. Brain Res Bull 1999, 50, 179-186.
7.
Nurse S, Corbett D: Neuroprotection after several days of mild, druginduced hypothermia. J Cereb Blood Flow Metab 1996, 16, 474-480.
8.
Schielke GP, Kupina NC, Boxer PA, Bigge CF, Welty DF, Iadecola C: The neuroprotective eff ect of the novel AMPA receptor antagonist PD152247 (PNQX) in temporary focal ischemia in the rat. Stroke 1999, 30, 1472-1477.
9.
De Vry J, Horvath E, Schreiber R: Neuroprotective and behavioural eff ects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. Eur J Pharmacol 2001, 428, 203-214.
10.
Gołembiowska K, Konieczny J, Wolfarth S, Ossowska K: Neuropro tective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outfl ow and inhibition of hyperthermia in rats. Neuropharmacology 2003, 45, 484 492.
11.
Battaglia G, Fornai F, Busceti CL, Aloisi G, Cerrito F, De Blasi A, Melchiorri D, Nicoletti F: Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci 2002, 22, 2135-2141.
12.
Łuszczki JJ, Borowicz KK, Czuczwar SJ: Non-competitive metabotropic glutamate subtype 5 receptor antagonist (SIB-1893) decreases body temperature in rats. Pharmacol Rep 2005, 57, 795-801.
13.
Borowicz KK, Łuszczki JJ, Czuczwar SJ: SIB 1893, a selective mGluR5 receptor antagonist, potentiates the anticonvulsant activity of oxcarbazepine against amygdala-kindled convulsions in rats. Pol J Pharmacol 2004, 56, 459-464.
14.
Kort WJ, Hekking-Weijma JM, TenKate MT, Sorm V, VanStrik R: A microchip implant system as a method to determine body temperature of terminally ill rats and mice. Lab Anim 1998, 32, 260-269.
15.
Schachter SC: Oxcarbazepine: current status and clinical applications. Expert Opin Investig Drugs 1999, 8, 1103-1112.
16.
O’Leary DM, Movsesyan V, Vicini S, Faden AI: Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamatemediated neuronal toxicity through actions that refl ect NMDA receptor antagonism. Br J Pharmacol 2000, 131, 1429-1437.
Share
RELATED ARTICLE
| eISSN: | 1898-7516 |
| ISSN: | 1898-2395 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
